Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for moderately to severely active ulcerative colitis with an eosinophilic phenotype
jRCT2031220662Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Dupilumab with Placebo (2 arms). Primary endpoint: Clinical response at Week 24. Started Apr 2023; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031220662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220662.